In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Andrew McConaghie

Senior Writer

Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.

He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.

Latest From Andrew McConaghie

Roche Tries Again With Failed Huntington’s Drug Tominersen

Despite disappointment in its Phase III study, Roche is preparing a new trial of the antisense therapy in patients with a lower disease burden.

Rare Diseases Clinical Trials

Selling Consumer Division To Unilever Could Give ‘New GSK’ A Lift

Activist investors last year called for GSK to find an outright buyer for the consumer division, and may now get their wish.

Companies Commercial

Caribou Prepares To Unveil Data On PD-1 Knock Out CAR-T

Proof of concept for Caribou’s gene-editing tweaks is just around the corner, but competition is intense in the allogeneic CAR-T field.

Cancer Companies

Intellia To Take On Pfizer Blockbuster With Gene-Editing Therapy

After achieving a landmark in gene-editing with NTLA-2001, Intellia moves to expand its reach into a larger market.

Companies Clinical Trials

After Setbacks, Confidence Grows In Likely Success For Sarepta’s Duchenne Gene Therapy

CEO tells J.P. Morgan conference that he is confident the pivotal EMBARK study can be completed in 2022 with regulatory filing in 2023.

Companies Clinical Trials

Sanofi Exit From Sickle Cell Gene Therapy Leaves Sangamo With Difficult Decision

Sanofi’s decision is influenced by its own in-house options, but also by the growing competition in sickle cell gene therapy.

Companies Commercial
See All
UsernamePublicRestriction

Register